- Hypertension is a common condition with a global prevalence of over 30% in adults, posing a risk for dangerous comorbidities like cardiovascular disease.
- Esaxerenone is a novel antihypertensive drug with potential benefits, including higher selectivity and improved safety profile compared to existing medications.
- The EXCITE-HT study compared esaxerenone to trichlormethiazide in a Japanese population with uncontrolled hypertension over 12 weeks.
- Esaxerenone demonstrated superior morning home blood pressure reduction compared to trichlormethiazide, potentially reducing cardiovascular risk.
- The study findings suggest that esaxerenone can be a suitable replacement or alternative to trichlormethiazide for Japanese patients with hypertension.
Source link
Cardiology,Nephrology,Internal Medicine